Literature DB >> 26971470

Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia.

Mei Hong Xiu1, Li Tian2, Song Chen1, Yun Long Tan1, Da Chun Chen1, Jing Chen3, Nan Chen1, Fu De Yang1, Julio Licinio4, Thomas R Kosten5, Jair C Soares6, Xiang Yang Zhang7.   

Abstract

Numerous studies have shown that proinflammatory cytokines produced by immune cells in the brain have deleterious effects on cognitive functions. In contrast, IL-10, an anti-inflammatory cytokine, can be neuroprotective and prevent neuronal dysfunction. However, few studies have linked the role of IL-10 to cognitive deficits in schizophrenia. In this study, serum IL-10 levels and genotypes for the IL10 -592 A/C promoter polymorphism were measured in a cohort of first-episode drug-naïve schizophrenic patients (FEDN-S) (n=256) and healthy control subjects (HC) (n=540). All participants were assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and psychopathology was assessed by the Positive and Negative Syndrome Scale (PANSS). In a separate transcriptomic data set containing 577 healthy human brain samples, we analyzed IL-10 and IL-10 RA/B-associated genetic networks in order to ascertain potential functions for IL-10 in the brain. We found a significant difference in allelic frequency between FEDN-S and HC subjects. The A allelic variant was associated with reduced serum IL-10 levels and worse attentional performance in FEDN-S but not in HC subjects. Moreover, serum IL-10 levels were correlated with the extent of cognitive impairment, especially attentional performance in the schizophrenic A-allele carriers. In human brain transcriptomic coexpression analysis, we found that genes most significantly co-expressed with IL10 were associated with synaptic vesicle transportation, and both IL10RA and IL10RB were most significantly co-expressed not only with genes that regulate inflammation but also with those that participate in synaptic formation. The IL10-592 A/C genetic variant was more common in schizophrenic patients than HC and was associated with lower IL-10 serum levels and worse attentional performance in these patients. Furthermore, the IL10 gene and its receptors in the healthy human brain appear to regulate inflammation and synaptic functions that are important for cognition, and hence its deficiency in schizophrenia may contribute to cognitive impairment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Cytokines; Genotype; Interleukin-10; Polymorphism; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 26971470     DOI: 10.1016/j.bbi.2016.03.005

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  15 in total

1.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

Review 2.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

3.  Serum ApoB levels in depressive patients: associated with cognitive deficits.

Authors:  Li Hui; Mei Han; Xiang Dong Du; Bao Hua Zhang; Shu Chang He; Tian Nan Shao; Guang Zhong Yin
Journal:  Sci Rep       Date:  2017-01-05       Impact factor: 4.379

4.  CD226 deficiency improves cognitive functions and ameliorates anxiety-like behaviors in mice.

Authors:  Liang Fang; Jingyi Jin; Ping Chen; Ning Wang; Hanyu Zeng; Boquan Jin; Hui Li; Lihua Chen
Journal:  Brain Behav       Date:  2017-11-22       Impact factor: 2.708

5.  BIS-guided deep anesthesia decreases short-term postoperative cognitive dysfunction and peripheral inflammation in elderly patients undergoing abdominal surgery.

Authors:  Chengxuan Quan; Jia Chen; Yuting Luo; Lei Zhou; Xi He; Yan Liao; Jing Chou; Qulian Guo; Alex F Chen; Ouyang Wen
Journal:  Brain Behav       Date:  2019-02-27       Impact factor: 2.708

6.  Relationships between abnormal neural activities and cognitive impairments in patients with drug-naive first-episode schizophrenia.

Authors:  Wei Yan; Rongrong Zhang; Min Zhou; Shuiping Lu; Wenmei Li; Shiping Xie; Ning Zhang
Journal:  BMC Psychiatry       Date:  2020-06-05       Impact factor: 3.630

Review 7.  Advancing study of cognitive impairments for antipsychotic-naïve psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology.

Authors:  Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone
Journal:  Schizophr Res       Date:  2020-04-05       Impact factor: 4.939

Review 8.  Cytokine Alterations in Schizophrenia: An Updated Review.

Authors:  Sara Momtazmanesh; Ameneh Zare-Shahabadi; Nima Rezaei
Journal:  Front Psychiatry       Date:  2019-12-06       Impact factor: 4.157

9.  Neuregulin 3 rs10748842 polymorphism contributes to the effect of body mass index on cognitive impairment in patients with schizophrenia.

Authors:  Yongjie Zhou; Yuhuan Li; Yujie Meng; Jiesi Wang; Fengchun Wu; Yuping Ning; Yi Li; Ryan M Cassidy; Zezhi Li; Xiang Yang Zhang
Journal:  Transl Psychiatry       Date:  2020-02-11       Impact factor: 6.222

10.  IL-35 polymorphisms and cognitive decline did not show any association in patients with coronary heart disease over a 2-year period: A retrospective observational study (STROBE compliant).

Authors:  Ying Shi; Shu Zhang; Yan Xue; Zicong Yang; Yingzhong Lin; Ling Liu; Hairun Liu
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.